CV
CapsoVision, Inc.12.00
-1.78-12.9%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
562.12MP/E (TTM)
-Basic EPS (TTM)
-0.48Dividend Yield
0%Recent Filings
8-K
8-K
CFO steps down abruptly
CapsoVision's CFO Kevin Lundquist stepped down effective August 27, 2025, prompting a search for his successor. Under the separation agreement, he receives six months' base salary, a $33,333.33 prorated bonus, accelerated vesting of options for 86,806 shares exercisable until September 1, 2028, and COBRA coverage. Lundquist will consult through February 28, 2026. Leadership transition underway.
8-K
Q2 revenue up 17%
CapsoVision reported Q2 2025 revenue of $3.3 million, up 17% from Q2 2024, fueled by higher CapsoCam Plus sales and 75% growth in new accounts. Gross profit rose to $1.8 million at 55% margin, while operating expenses dipped to $6.5 million, narrowing net loss to $4.6 million. The July IPO injected $23.4 million in net proceeds, bolstering cash from $1.1 million. FDA submission for CapsoCam Colon signals pipeline expansion, yet regulatory risks loom.
10-Q
Q2 FY2025 results
CapsoVision posted solid Q2 revenue growth of 17% year-over-year to $3.3M, driven by higher CapsoCam Plus capsule sales, while gross margin held steady at 55% despite competitive pricing pressures. Operating loss narrowed 12% to $4.7M as R&D costs dropped 20% following completion of the CapsoCam Colon pivotal study, though G&A rose on professional fees. Cash burned $9.5M in H1, leaving $1.1M at quarter-end, with the July IPO netting $23.4M to fund commercialization; free cash flow not disclosed in the 10-Q. The firm filed for initial CapsoCam Colon clearance in June, targeting Q2 2026 launch after second-arm study. Revenue remains tied to small-bowel sales amid regulatory hurdles. Competition from established players like Medtronic poses ongoing market risks.
8-K
Canon sensor development deal
CapsoVision inked a deal with Canon on July 15, 2025, to develop CMOS image sensors for future capsule endoscopes, paying $4.1 million total—$1 million upfront, the rest via added unit prices on future purchases. This bolsters tech for post-FDA clearance products, while underwriters exercised an overallotment option on July 16, netting $600,000 more from 129,978 shares. Future sensors target enhanced evaluations. Delays risk termination.
AVNS
Avanos Medical, Inc.
11.62-0.24
BSX
Boston Scientific Corporation
92.95+0.76
CBLL
CeriBell, Inc.
21.99+0.09
CVRX
CVRx, Inc.
8.32+0.14
ECIA
Encision, Inc.
0.15+0.00
ENOV
Enovis Corporation
26.07-0.47
LUCD
Lucid Diagnostics Inc.
1.12+0.01
PAVM
PAVmed Inc.
0.31-0.01
VTAK
Catheter Precision, Inc.
2.19-0.04
VYCO
Vycor Medical, Inc.
0.16+0.00